Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blue Sun Mycology Group is a private Oregon-based mycology and psychedelic biotech company focused on breeding novel fungi and developing fungi-derived natural product extracts and compounds. The company has described proprietary methods for sexual hybridization, somatic hybridization, and related breeding approaches intended to create new interspecific and intergeneric fungal organisms, including psychoactive fungi. Its public disclosures emphasize intellectual property generation, fungal strain development, extraction, and potential downstream applications in medicinal, industrial, and consumer markets rather than an established clinical drug pipeline. Blue Sun has also discussed psilocybin- and psilocin-dominant extracts and future participation in emerging legal psychedelic markets. Overall, the company appears to be an early-stage platform and product developer operating at the intersection of mycology, natural products, and psychedelic biotechnology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Blue Sun Mycology Group.